| P50 | author | Srdan Verstovsek | Q64026418 |
| | Prithviraj Bose | Q88053364 |
| P2093 | author name string | Prithviraj Bose | |
| P2860 | cites work | Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control | Q24297854 |
| | Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis | Q24316448 |
| | JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin | Q24318979 |
| | Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 |
| | Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent | Q27681086 |
| | Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML | Q27852275 |
| | Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib | Q27853179 |
| | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 |
| | Jak2 is essential for signaling through a variety of cytokine receptors | Q28270987 |
| | Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms | Q28271752 |
| | Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 |
| | A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 |
| | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 |
| | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis | Q62818096 |
| | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 |
| | Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q85722774 |
| | Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia | Q89165389 |
| | Activated Jak2 with the V617F point mutation promotes G1/S phase transition | Q40288678 |
| | Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). | Q40408575 |
| | The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis | Q40625383 |
| | Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. | Q40742224 |
| | JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms | Q41127061 |
| | JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 |
| | Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor | Q41411411 |
| | The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies | Q42335807 |
| | Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. | Q42344556 |
| | Thrombopoietin receptor is required for the oncogenic function of CALR mutants. | Q42365043 |
| | The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis | Q42385052 |
| | A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process | Q43237567 |
| | The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 |
| | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 |
| | Mutations and prognosis in primary myelofibrosis | Q44429606 |
| | Progressive multifocal leukoencephalopathy associated with ruxolitinib | Q44509111 |
| | Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. | Q45350105 |
| | Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation | Q46528151 |
| | Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology | Q47606460 |
| | The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy | Q48636417 |
| | In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia | Q50241082 |
| | Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. | Q50498488 |
| | Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib. | Q50908795 |
| | Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. | Q52564601 |
| | Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. | Q53096529 |
| | Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. | Q53154624 |
| | Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. | Q53164149 |
| | The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. | Q53207496 |
| | Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? | Q54337792 |
| | Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. | Q54721275 |
| | Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. | Q55055726 |
| | Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera | Q58416020 |
| | Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy | Q38824881 |
| | Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial | Q38909050 |
| | Ruxolitinib dose management as a key to long-term treatment success | Q38938939 |
| | Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. | Q38966659 |
| | Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms | Q38984578 |
| | Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms | Q39059549 |
| | Does ruxolitinib prolong the survival of patients with myelofibrosis? | Q39061497 |
| | Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells | Q39187734 |
| | Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms | Q39528530 |
| | Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence | Q39554738 |
| | JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation | Q39593309 |
| | Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report | Q40045490 |
| | Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. | Q40085126 |
| | The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis | Q40197045 |
| | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). | Q33405372 |
| | Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. | Q33410346 |
| | Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Q33411211 |
| | Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia | Q33417454 |
| | Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. | Q33419957 |
| | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | Q33420037 |
| | Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis | Q33421108 |
| | A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) | Q33429873 |
| | Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial | Q33432637 |
| | A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis | Q33434284 |
| | A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis | Q33435398 |
| | Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis | Q33436345 |
| | Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study | Q33437373 |
| | Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies | Q33437478 |
| | Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial | Q33439559 |
| | Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial | Q33440361 |
| | Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis | Q33697252 |
| | Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls | Q33843390 |
| | Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells | Q33854194 |
| | Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms | Q33880512 |
| | Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms | Q33982315 |
| | Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 |
| | HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans | Q34162151 |
| | GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. | Q34342071 |
| | CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. | Q34485103 |
| | Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia | Q34541588 |
| | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 |
| | A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. | Q35206418 |
| | Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. | Q35634902 |
| | Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase | Q35988523 |
| | Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. | Q36003480 |
| | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis | Q36091279 |
| | Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera | Q36169783 |
| | A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis | Q36708975 |
| | A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. | Q36717896 |
| | Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation | Q36853951 |
| | Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs | Q36915139 |
| | Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera | Q36938773 |
| | Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis | Q37034988 |
| | Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. | Q37097096 |
| | Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q37163487 |
| | Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis | Q37197964 |
| | Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis | Q37216367 |
| | Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. | Q37272164 |
| | The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition | Q37334721 |
| | Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation | Q37441169 |
| | Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. | Q37460337 |
| | Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors | Q37503137 |
| | Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies | Q37552023 |
| | Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis | Q37555309 |
| | The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). | Q37561170 |
| | Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms | Q37670068 |
| | Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. | Q37708936 |
| | A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence | Q37740928 |
| | PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis | Q37770220 |
| | A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis | Q38097556 |
| | Does anything work for anaemia in myelofibrosis? | Q38246165 |
| | Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling | Q38297889 |
| | Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. | Q38393343 |
| | Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial | Q38407900 |
| | Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group | Q38570614 |
| | Investigational Janus kinase inhibitors in development for myelofibrosis | Q38691019 |
| | Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells | Q38716411 |
| | Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. | Q38799094 |
| | Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. | Q38811734 |
| | Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis | Q38816577 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 115-125 | |
| P577 | publication date | 2017-05-12 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | JAK2 inhibitors for myeloproliferative neoplasms: what is next? | |
| P478 | volume | 130 | |